Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exjade in Iron Overload in Aplastic Anemia
NCT01818726Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jun 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of deferasirox in iron overload (2 arms), sponsored by Novartis. Primary endpoints: Change in Serum Ferritin Values at Week 52, Change in Transferrin Saturation With Iron (TSI) Values at Week 52 and 1 more. Started Jun 2014; status: terminated.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT01818726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818726.